TETRACYCLINE HYDROCHLORIDE | N050493 | SHIRE DEVELOPMENT INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 4 | Completed | Johns Hopkins University | 1,452 | 2001-08 → 2006-12 | |
| N/A | Completed | Seoul National University Bundang Hospital | 390 | 2014-07 → 2016-04 | |
| N/A | Completed | Kaohsiung Veterans General Hospital. | 126 | 2012-08-01 → 2021-10-31 | |
| Phase 2 | Completed | Huntington Medical Research Institutes | 13 | 2011-09 → 2012-10 | |
| Phase 4 | Completed | National Taiwan University Hospital | 589 | 2015-07 → 2018-05 | |
| Phase 3 | Completed | The Forsyth Institute | 187 | 1999-09 → 2004-12 | |
| Phase 4 | Completed | Shanghai Jiao Tong University School of Medicine | 200 | 2012-11 → 2013-04 | |
| Phase 4 | Completed | Seoul National University Bundang Hospital | 648 | 2003-01 → 2010-12 | |
| N/A | Completed | The University of Hong Kong | 391 | 2011-05 → 2012-12 | |
| N/A | Completed | Kaohsiung Veterans General Hospital. | 102 | 2015-02 → 2017-09 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
5 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
No patent or exclusivity listings for this strength.